Raquel Hladun Alvaro I hold a degree in Medicine and Surgery from the Universitat de Barcelona and completed my medical residency in Pediatrics and its Specific Areas at Vall d’Hebron University Hospital. I undertook a fellowship in Pediatric Oncology and Hematology at Vall d’Hebron Hospital in Barcelona and completed my training with a fellowship in new drug development at Gustave Roussy, an internationally renowned center for pediatric cancer treatment. Institutions of which they are part Predoctoral researcher Childhood Cancer and Blood Disorders Vall Hebron Institut de Recerca Doctor Paediatric Oncology and Haematology Children's Hospital and Woman's Hospital Raquel Hladun Alvaro Institutions of which they are part Predoctoral researcher Childhood Cancer and Blood Disorders Vall Hebron Institut de Recerca Doctor Paediatric Oncology and Haematology Children's Hospital and Woman's Hospital I hold a degree in Medicine and Surgery from the Universitat de Barcelona and completed my medical residency in Pediatrics and its Specific Areas at Vall d’Hebron University Hospital. I undertook a fellowship in Pediatric Oncology and Hematology at Vall d’Hebron Hospital in Barcelona and completed my training with a fellowship in new drug development at Gustave Roussy, an internationally renowned center for pediatric cancer treatment.
Since 2017, I have worked as a Consultant in the Pediatric Oncology Department at Vall d’Hebron Hospital. I am currently responsible for pediatric soft tissue sarcomas, pediatric liver tumors, and pediatric precision medicine. I am also part of the Childhood Cancer Research Group at the Vall d’Hebron Institute of Research (VHIR), where I actively participate in the Sarcoma Laboratory and the Personalized Medicine Program. I serve as the National Coordinator in Spain for the clinical trial FaR-RMS for newly diagnosed and relapsed patients, developed by the European Pediatric Soft Tissue Sarcoma Group (EpSSG). I lead the Soft Tissue Sarcoma Working Group of the Sociedad Española de Hematología y Oncología Pediátricas (SEHOP) and am an active member of the EpSSG Phase I/II Committee. I am also part of SEHOP’s Personalized Medicine Working Group and a member of the European consortium Innovative Therapies for Children with Cancer (ITCC). I participate as a co-investigator in major personalized medicine projects, such as the European program MAPPYACTS (MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification) and the national program SEHOP-PENCIL (Personalised mEdiciNe for Cancer in chILdren in Spain).
Projects Nuevas estrategias de inhibición de la vía Hedgehog como dianas terapéuticas en el rabdominosarcoma. IP: Josep Roma Castanyer Collaborators: Soledad Gallego Melcón, Josep Sánchez de Toledo Codina, Anna Llort Sales, Raquel Hladun Alvaro, Patricia Zarzosa Martinez Funding agency: Instituto de Salud Carlos III Funding: 87120 Reference: PI18/00398 Duration: 01/01/2019 - 31/12/2021 Investigació translacional en càncer infantil (GRE) IP: Josep Sánchez de Toledo Codina Collaborators: Soledad Gallego Melcón, Aroa Soriano Fernández, Maria Cristina Díaz de Heredia Rubio, Miguel Segura Ginard, Anna Llort Sales, Raquel Hladun Alvaro, Laura Alonso Garcia, Josep Roma Castanyer Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 30000 Reference: 2014 SGR 660 Duration: 01/01/2014 - 31/12/2016 Phase I/II Gene Therapy Trial of Fanconi anemia patients with a new Orphan Drug consisting of a lentiviral vector carrying the FANCA gene: A Coordinated International Action (EUROFANCOLEN) Grant Agreement nº 305421 IP: Josep Sánchez de Toledo Codina Collaborators: Jordi Barquinero Mañez, Maria Cristina Díaz de Heredia Rubio, Raquel Hladun Alvaro Funding agency: EUROPEAN COMMISSION Funding: 285000 Reference: EUROFANCOLEN_FP7HEALTH2012 Duration: 01/01/2013 - 31/12/2018 Ensayo clínico Fase I/II para evaluar la seguridad y eficacia de la movilización y colecta de células CD34+ tras tratamiento con plerixafor y filgrastim en pacientes con Anemia de Fanconi para su posterior uso en ensayos de terapia génica IP: Maria Cristina Díaz de Heredia Rubio Collaborators: Josep Sánchez de Toledo Codina, Raquel Hladun Alvaro Funding agency: Ministerio Sanidad Funding: 437580 Reference: EC11-559 Duration: 01/01/2012 - 30/06/2018 Pagination First page « Previous page ‹ Page 1 Page 2 Current page 3
